IPI-549|IPI549|PI3K-gamma inhibitor

IPI-549|IPI549|PI3K-gamma inhibitor

IPI-549 in stock, 800 USD/100mg. IPI-549 is an orally administered immuno-oncology development candidate that selectively inhibits PI3K-gamma.

Product Name: IPI-549 |cas: N/A |cat number: DC9829 |Molecule Formular: C30H24N8O2 |MW: 528.2 |purity>98%

IPI-549 is an orally administered immuno-oncology development candidate that selectively inhibits PI3K-gamma. In preclinical studies, IPI-549 inhibits immune-suppressive macrophages within the tumor microenvironment, whereas other immunotherapies such as checkpoint modulators more directly target immune effector cell function. As such, IPI-549 may have the potential to treat a broad range of solid tumors and represents a potentially complementary approach to restoring anti-tumor immunity in combination with other immunotherapies such as checkpoint inhibitors.

For research only, not for human use.